Anaemia of Chronic Disease: An In-Depth Review

Medical Principles and Practice

Volumn 26, Issue 1, 2017, Pages 1-9

  Madu, Anazoeze Jude ^a   Ughasoro, Maduka Donatus ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Anaemia; Chronic disease inflammation; Cytokines; Ferritin; Hepcidin; Pathogenesis

Indexed keywords

ANTIANEMIC AGENT; CYTOKINE; ERYTHROPOIETIN; FERRITIN; FERRITIN RECEPTOR; HEPCIDIN; IRON; RECEPTOR; UNCLASSIFIED DRUG; INTERLEUKIN 6;

ANEMIA; ANEMIA OF CHRONIC DISEASE; BONE MARROW DISEASE; DRUG TARGETING; DRUG TREATMENT FAILURE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE STRUCTURE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HUMAN; HYPOFERREMIA; IRON METABOLISM; IRON METABOLISM DISORDER; IRON THERAPY; LABORATORY DIAGNOSIS; NONHUMAN; PATHOGENESIS; REGULATORY MECHANISM; RETICULOENDOTHELIAL SYSTEM; REVIEW; TREATMENT RESPONSE; AGE; CHRONIC DISEASE; COMPLICATION; DIFFERENTIAL DIAGNOSIS; PATHOPHYSIOLOGY;

AGE FACTORS; ANEMIA; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; ERYTHROPOIESIS; HUMANS; INTERLEUKIN-6; IRON METABOLISM DISORDERS;

EID: 84989259693     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000452104     Document Type: Review

References (58)

1. Poggiali E, Migone Amicis M, Motta I: Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014; 25: 12-17
2. Weiss G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16: 87-96
3. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
4. Means RT Jr: Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003; 2: 116-121
5. Weiss G: Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-693
6. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
7. Zupanic K, Sucic M, Bekic D: Anemia of chronic disease: illness or adaptive mechanism. Acta Clin Croat 2014; 53: 348-354
8. Theurl M, Nairz M, Schroll A, et al: Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica 2014; 99: 1516-1524
9. Gaspar BL, Sharma P, Das R: Anemia in malignancies: pathogenetic and diagnostic considerations. Hematology 2015; 20: 18-25
10. Gangat N, Wolanskyj AP: Anemia of chronic disease. Semin Hematol 2013; 50: 232-238
11. Capocasale RJ, Makropoulos DA, Achuthanandam R, et al: Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice. Cytometry A 2008; 73: 148-159
12. Lima GA, Mazzali M, Gentil AF, et al: Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolism in patients not submitted to dialysis treatment. Clin Lab 2012; 58: 695-704
13. Moldawer LL, Marano MA, Wei H, et al: Cachectin/ tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3: 1637-1643
14. McCranor BJ, Kim MJ, Cruz NM, et al: Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis 2014; 52: 126-133
15. Gifford GE, Duckworth DH: Introduction to TNF and related lymphokines. Biotherapy 1991; 3: 103-111
16. Galushko EA: The clinical significance of hepcidin detection in the patients with anemia and rheumatoid arthritis (in Russian). Klin Med (Mosk) 2014; 92: 21-27
17. Nemeth E, Valore EV, Territo M, et al: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463
18. Raj DS: Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009; 38: 382-388
19. Katsoulidis E, Li Y, Yoon P, et al: Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005; 65: 9029-9037
20. Lortz S, Schroter S, Stuckemann V, et al: Influence of cytokines on DMT1 iron transporter and ferritin expression in insulin-secreting cells. J Mol Endocrinol 2014; 52: 301-310
21. Costa E, Fernandes J, Ribeiro S, et al: Aging is associated with impaired renal function, INFgamma induced inflammation and with alterations in iron regulatory proteins gene expression. Aging Dis 2014; 5: 356-365
22. Kheansaard W, Mas-Di S, Nilganuwong S, et al: Interferon-gamma induced nitric oxidemediated apoptosis of anemia of chronic disease in rheumatoid arthritis. Rheumatol Int 2013; 33: 151-156
23. Vokurka M, Krijt J, Vavrova J, et al: Hepcidin expression in the liver of mice with implanted tumour reacts to iron deficiency, inflammation and erythropoietin administration. Folia Biol (Praha) 2011; 57: 248-254
24. Becker C, Orozco M, Solomons NW, et al: Iron metabolism in obesity: how interaction between homoeostatic mechanisms can interfere with their original purpose. I. Underlying homoeostatic mechanisms of energy storage and iron metabolisms and their interaction. J Trace Elem Med Biol 2015; 30: 195-201
25. Ganz T, Nemeth E: Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823: 1434-1443
26. Brasse-Lagnel C, Karim Z, Letteron P, et al: Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology 2011; 140: 1261-1271. e1261
27. Sun CC, Vaja V, Babitt JL, et al: Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392-400
28. Schubert TE, Echtenacher B, Hofstadter F, et al: Failure of interferon-gamma and tumor necrosis factor in mediating anemia of chronic disease in a mouse model of protracted septic peritonitis. Int J Mol Med 2005; 16: 753-758
29. Kumar M, Bhoi S: Cytokines, granulocytemonocyte colony stimulating factor, interleukin-3 and erythropoietin: can they be a therapeutic option for the stimulation of hematopoietic progenitor cells in trauma-hemorrhagic shock? Indian J Crit Care Med 2016; 20: 207-209
30. Langdon JM, Yates SC, Femnou LK, et al: Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol 2014; 89: 470-479
31. Besson-Fournier C, Latour C, Kautz L, et al: Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 2012; 120: 431-439
32. Masson C: Rheumatoid anemia. Joint Bone Spine 2011; 78: 131-137
33. Lurdes Agostinho Cabrita A, Pinho A, Malho A, et al: Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol 2011; 43: 835-840
34. Nazemian F, Karimi G, Moatamedi M, et al: Effect of silymarin administration on TNFalpha serum concentration in peritoneal dialysis patients. Phytother Res 2010; 24: 1654-1657
35. Icardi A, Paoletti E, De Nicola L, et al: Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 2013; 28: 1672-1679
36. Bel'mer SV, Mitina EV, Karpina LM, et al: Iron deficiency anemia and anemia in chronic celiac disease in children. Eksp Klin Gastroenterol 2014; 23-29
37. Panichi V, Rosati A, Paoletti S, et al: A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif 2011; 32: 7-14
38. Ludwiczek S, Aigner E, Theurl I, et al: Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148-4154
39. Lopez-Prieto J, Gonzalez-Reimers E, Aleman-Valls MR, et al: Iron and proinflammatory cytokines in chronic hepatitis C virus infection. Biol Trace Elem Res 2013; 155: 5-10
40. Ravasi G, Pelucchi S, Greni F, et al: Circulating factors are involved in hypoxia-induced hepcidin suppression. Blood Cells Mol Dis 2014; 53: 204-210
41. Sonnweber T, Nachbaur D, Schroll A, et al: Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 2014; 63: 1951-1959
42. Zhang S, Chen Y, Guo W, et al: Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell Signal 2014; 26: 2539-2550
43. Xu X, Jiang M, Zhang Y, et al: Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. Mol Med Rep 2015; 11: 289-294
44. Mei S, Wang H, Fu R, et al: Hepcidin and GDF15 in anemia of multiple myeloma. Int J Hematol 2014; 100: 266-273
45. Jiang F, Yu WJ, Wang XH, et al: Regulation of hepcidin through GDF-15 in cancer-related anemia. Clin Chim Acta 2014; 428: 14-19
46. Unal B, Alan S, Bassorgun CI, et al: The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies. Arch Dermatol Res 2015; 307: 551-557
47. Spivak JL: Iron and the anemia of chronic disease. Oncology (Williston Park) 2002; 16: 25-33
48. Przybyszewska J, Zekanowska E, Kedziora-Kornatowska K, et al: Serum prohepcidin and other iron metabolism parameters in elderly patients with anemia of chronic disease and with iron deficiency anemia. Pol Arch Med Wewn 2013; 123: 105-111
49. Shu T, Jing C, Lv Z, et al: Hepcidin in tumorrelated iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol 2015; 94: 67-73
50. Nairz M, Haschka D, Demetz E, et al: Iron at the interface of immunity and infection. Front Pharmacol 2014; 5: 152
51. Kennedy RB, Ovsyannikova IG, Haralambieva IH, et al: Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics 2014; 66: 493-499
52. Blumenstein I, Dignass A, Vollmer S, et al: Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis 2014; 8: 1308-1314
53. Derovs A, Pokrotnieks J, Derova J, et al: Current opinion on the management of iron deficiency anaemia in gastrointestinal diseases. Eksp Klin Gastroenterol 2014; 97-105
54. Herfs R, Fleitmann L, Kocsis I: Treatment of iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices-A non-interventional study. Geburtshilfe Frauenheilkd 2014; 74: 81-88
55. Bergamaschi G, Di Sabatino A, Albertini R, et al: Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010; 95: 199-205
56. Miyazono K, Kamiya Y, Morikawa M: Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51
57. Han X, Zhou DB, Xu CM, et al: Effect of erythropoietin on proinflammatory factors of human monocytes and its mechanisms (in Chinese). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19: 738-743
58. Schwoebel F, van Eijk LT, Zboralski D, et al: The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013; 121: 2311-2315